Catherine StehmanBreen - Sarepta Therapeutics Senior Vice President Chief Medical Officer
| SRPT Stock | USD 126.66 2.14 1.66% |
President
Dr. Catherine StehmanBreen, M.D., is Senior Vice President, Chief Medical Officer of the Company. Dr. StehmanBreen served as Vice President, Clinical Development and Regulatory Affairs at Regeneron Pharmaceuticals Inc., a biotechnology company, initially as Head, Pain Therapeutic Area, and subsequently as Head, Clinical Project Management and Operations. From 2003 to 2015, she held senior leadership roles at Amgen Inc., a pharmaceutical company, including Vice President, Global Development, leading the neuroscience, nephrology and bone therapeutic areas. Dr. StehmanBreen spent six years as a faculty member in the Division of Nephrology at the University of Washington from 1997 to 2003, where her primary responsibilities included managing the Clinical Research Training Program and the development of the Epidemiology and Clinical Trials Research Program since 2017.
| Age | 53 |
| Tenure | 7 years |
| Address | 215 First Street, Cambridge, MA, United States, 02142 |
| Phone | 617 274 4000 |
| Web | https://www.sarepta.com |
Sarepta Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.0524) % which means that it has lost $0.0524 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.8615) %, meaning that it created substantial loss on money invested by shareholders. Sarepta Therapeutics' management efficiency ratios could be used to measure how well Sarepta Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.17 in 2024. Return On Capital Employed is likely to drop to -0.11 in 2024. At this time, Sarepta Therapeutics' Total Current Liabilities is comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 3.4 B in 2024, whereas Non Current Liabilities Other is likely to drop slightly above 39 M in 2024.Similar Executives
| Found 9 records | PRESIDENT Age | ||
| Rebecca Taub | Madrigal Pharmaceuticals | 66 | |
| Catherine Kelleher | Viking Therapeutics | N/A | |
| Suma Krishnan | Krystal Biotech | 59 | |
| Greg Zante | Viking Therapeutics | N/A | |
| Gregory Zante | Viking Therapeutics | 53 | |
| Marc Schneebaum | Madrigal Pharmaceuticals | 64 | |
| Erin MD | Terns Pharmaceuticals | 53 | |
| Amy Broidrick | Viking Therapeutics | N/A | |
| Wendy Rieder | Madrigal Pharmaceuticals | 46 | |
Management Performance
| Return On Equity | -0.86 | ||||
| Return On Asset | -0.0524 |
Sarepta Therapeutics Leadership Team
Elected by the shareholders, the Sarepta Therapeutics' board of directors comprises two types of representatives: Sarepta Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sarepta. The board's role is to monitor Sarepta Therapeutics' management team and ensure that shareholders' interests are well served. Sarepta Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sarepta Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Edward Kaye, Senior Vice President Chief Medical Officer | ||
| Alexander Cumbo, Vice President Head of Commercial | ||
| William Ciambrone, Ex Operations | ||
| Dallan Murray, Executive Officer | ||
| Hans Wigzell, Independent Director | ||
| Michael Bonney, Director | ||
| Sandesh Mahatme, CFO, Chief Accounting Officer and Sr. VP | ||
| Ryan JD, General VP | ||
| Jayant Aphale, Senior Vice President - Technical Operations | ||
| Mary Gray, Director | ||
| Douglas Esq, CEO President | ||
| Anthony Chase, Independent Director | ||
| Douglas Ingram, President CEO | ||
| Gilmore ONeill, Senior Vice President Chief Medical Officer | ||
| JeanPaul Kress, Director | ||
| Joan Wood, Vice President - Human Resources | ||
| Alison Nasisi, Executive Officer | ||
| Bilal Arif, Executive Officer | ||
| Ryan Brown, Gen VP | ||
| Richard Barry, Independent Director | ||
| Gil Price, Independent Director | ||
| Catherine StehmanBreen, Senior Vice President Chief Medical Officer | ||
| David Howton, Sr. VP, General Counsel and Corporate Secretary | ||
| Mary Jenkins, Sr Relations | ||
| Ian Estepan, Executive CFO | ||
| Guriqbal Basi, Senior Vice President Chief Scientific Officer | ||
| Will Tilton, Head VP | ||
| William Goolsbee, Non-Executive Independent Chairman of the Board | ||
| Louise RodinoKlapac, Chief VP | ||
| Claude Nicaise, Independent Director | ||
| Kathleen Behrens, Independent Director | ||
| Diane Berry, Executive Officer | ||
| Erin Cox, IR Contact | ||
| Shamim Ruff, Senior Vice President - Regulatory Affairs and Quality | ||
| Francesca Nolan, Executive Communications |
Sarepta Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Sarepta Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.86 | ||||
| Return On Asset | -0.0524 | ||||
| Profit Margin | (0.43) % | ||||
| Operating Margin | 0.06 % | ||||
| Current Valuation | 11.81 B | ||||
| Shares Outstanding | 94.51 M | ||||
| Shares Owned By Insiders | 4.39 % | ||||
| Shares Owned By Institutions | 86.90 % | ||||
| Number Of Shares Shorted | 4.87 M | ||||
| Price To Earning | (20.43) X |
Sarepta Therapeutics Investors Sentiment
The influence of Sarepta Therapeutics' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Sarepta. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Sarepta Therapeutics' public news can be used to forecast risks associated with an investment in Sarepta. The trend in average sentiment can be used to explain how an investor holding Sarepta can time the market purely based on public headlines and social activities around Sarepta Therapeutics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Sarepta Therapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Sarepta Therapeutics' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Sarepta Therapeutics' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Sarepta Therapeutics.
Sarepta Therapeutics Implied Volatility | 147.43 |
Sarepta Therapeutics' implied volatility exposes the market's sentiment of Sarepta Therapeutics stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Sarepta Therapeutics' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Sarepta Therapeutics stock will not fluctuate a lot when Sarepta Therapeutics' options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Sarepta Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Sarepta Therapeutics' short interest history, or implied volatility extrapolated from Sarepta Therapeutics options trading.
Currently Active Assets on Macroaxis
When determining whether Sarepta Therapeutics is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Sarepta Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Sarepta Therapeutics Stock. Highlighted below are key reports to facilitate an investment decision about Sarepta Therapeutics Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sarepta Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. For more information on how to buy Sarepta Stock please use our How to Invest in Sarepta Therapeutics guide.You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Complementary Tools for Sarepta Stock analysis
When running Sarepta Therapeutics' price analysis, check to measure Sarepta Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sarepta Therapeutics is operating at the current time. Most of Sarepta Therapeutics' value examination focuses on studying past and present price action to predict the probability of Sarepta Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sarepta Therapeutics' price. Additionally, you may evaluate how the addition of Sarepta Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets |
Is Sarepta Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sarepta Therapeutics. If investors know Sarepta will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sarepta Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.80) | Revenue Per Share 13.456 | Quarterly Revenue Growth 0.535 | Return On Assets (0.05) | Return On Equity (0.86) |
The market value of Sarepta Therapeutics is measured differently than its book value, which is the value of Sarepta that is recorded on the company's balance sheet. Investors also form their own opinion of Sarepta Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Sarepta Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sarepta Therapeutics' market value can be influenced by many factors that don't directly affect Sarepta Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sarepta Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sarepta Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sarepta Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.